Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study

Eddy Barasch1, John S Gottdiener, Gerard Aurigemma

  • 1Department of Research and Education, St Francis Hospital/SUNY at Stony Brook, Roslyn, NY 11576, USA. eddy.barasch@chsli.org

Insights

Serum fibrosis markers are elevated in elderly individuals with heart failure (HF). These findings highlight potential biomarkers for HF in older populations.

Area of Science:

  • Cardiology
  • Biomarkers
  • Geriatrics

Background:

  • Myocardial fibrosis, characterized by excess collagen in the left ventricular matrix, is linked to heart failure (HF).
  • Previous research has not explored the relationship between fibrosis biomarkers and HF specifically in elderly populations.

Purpose of the Study:

  • To investigate the association between serum fibrosis biomarkers and heart failure (HF) in an elderly cohort.
  • To determine if these biomarkers differ between systolic HF, diastolic HF, and healthy controls.

Main Methods:

  • Serum samples from 880 elderly participants (mean age 77) in the Cardiovascular Health Study were analyzed for fibrosis markers.
  • Participants were categorized into systolic HF, diastolic HF, and control groups.
  • Logistic regression analysis was performed, adjusting for multiple covariates relevant to aging and cardiovascular health.

Main Results:

  • Elevated levels of carboxyl-terminal telopeptide of collagen type I and amino-terminal peptide of procollagen type III were significantly associated with both systolic and diastolic HF.
  • These associations remained significant after adjusting for various clinical factors.
  • Carboxyl-terminal peptide of procollagen type I did not show a significant association with HF.

Conclusions:

  • Serum fibrosis markers are significantly elevated in elderly individuals diagnosed with either diastolic or systolic heart failure.
  • These elevated markers persist even after accounting for other relevant covariates in the aging process.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...